Expertise in
4
conditions

Dr. Susan L. Koletar

Infectious Disease
Ohio State McCampbell Outpatient Care
1581 Dodd Dr, 
Columbus, OH 
Accepting New Patients
Offers Telehealth
Expertise in
4
conditions
Ohio State McCampbell Outpatient Care
1581 Dodd Dr, 
Columbus, OH 

Overview

Susan Koletar is an Infectious Disease provider practicing medicine in Columbus, Ohio.

Dr. Koletar is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses HIV/AIDS, Myelitis, AIDS Dementia Complex, and AIDS Dysmorphic Syndrome.

She is actively involved in clinical research, co-authoring 64 peer reviewed articles and participating in 10 clinical trials. Dr. Koletar is currently accepting new patients.

Specialties

Infectious Disease

Licenses

Internal Medicine in OH

Hospital Affiliations

Ohio State University State Health System

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Ohio State McCampbell Outpatient Care
1581 Dodd Dr, Columbus, OH 43210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Safety, Tolerability and Immunogenicity of Recombinant HIV Envelope Protein VRC-HIVRGP096-00-VP (Trimer 4571) Vaccine, in HIV-1 Infected Adults on Suppressive ART
Safety, Tolerability and Immunogenicity of Recombinant HIV Envelope Protein VRC-HIVRGP096-00-VP (Trimer 4571) Vaccine, in HIV-1 Infected Adults on Suppressive ART
Enrollment Status: Completed
Publish Date: January 22, 2026
Intervention Type: Biological
Study Drug: Trimer 4571 vaccine
Study Phase: Phase 1
A Phase I Study to Evaluate the Safety, Tolerability and Immunogenicity of a Therapeutic HIV Vaccine Composed of Autologous Dendritic Cells Loaded With Autologous Inactivated Whole Virus or Conserved Peptides in ART-treated HIV-infected Adults
A Phase I Study to Evaluate the Safety, Tolerability and Immunogenicity of a Therapeutic HIV Vaccine Composed of Autologous Dendritic Cells Loaded With Autologous Inactivated Whole Virus or Conserved Peptides in ART-treated HIV-infected Adults
Enrollment Status: Completed
Publish Date: October 29, 2025
Intervention Type: Biological
Study Drugs: a1DC + inactivated whole autologous HIV, a1DC + conserved HIV peptides, a1DC + no antigen, pgDC + inactivated whole autologous HIV, pgDC + conserved HIV peptides, pgDC + no antigena1DC
Study Phase: Phase 1
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Elvitegravir+Cobicistat+Emtricitabine+Tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Study Phase: Phase 2
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Phase: Phase 3
An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses
An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses
Enrollment Status: Completed
Publish Date: October 21, 2024
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Drug, Other
Study Phase: Phase 4
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Enrollment Status: Completed
Publish Date: January 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study
Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study
Enrollment Status: Completed
Publish Date: October 14, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blinded, Placebo-Controlled Trial of a Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin, Januvia) for Reducing Inflammation and Immune Activation in HIV-Infected Men and Women: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)
A Randomized, Double-Blinded, Placebo-Controlled Trial of a Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin, Januvia) for Reducing Inflammation and Immune Activation in HIV-Infected Men and Women: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)
Enrollment Status: Completed
Publish Date: June 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

64 Total Publications

Serum Biomarkers of Macrophage Activation and Incident CKD in People With and Without HIV: Findings From the MACS-WIHS Combined Cohort Study.
Serum Biomarkers of Macrophage Activation and Incident CKD in People With and Without HIV: Findings From the MACS-WIHS Combined Cohort Study.
Journal: Open forum infectious diseases
Published: February 11, 2026
Similar Doctors
Expertise in
12
conditions
Dr. Pablo J. Sanchez
Infectious Disease
Expertise in
12
conditions
Dr. Pablo J. Sanchez
Infectious Disease
Referral may be required

Nationwide Children's Hospital

700 Childrens Dr, 
Columbus, OH 
 (3.5 miles away)
614-722-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Pablo Sanchez is an Infectious Disease provider practicing medicine in Columbus, Ohio. Dr. Sanchez is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Congenital Cytomegalovirus, Congenital Syphilis, Cytomegalovirus Infection, and Cytomegalic Inclusion Disease. Dr. Sanchez is currently accepting new patients.

Expertise in
7
conditions
Dr. Jose A. Bazan
Infectious Disease
Expertise in
7
conditions
Dr. Jose A. Bazan
Infectious Disease
Referral may be required

Ohio State McCampbell Outpatient Care

1581 Dodd Dr, 
Columbus, OH 
 (0.1 miles away)
614-293-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jose Bazan is an Infectious Disease provider practicing medicine in Columbus, Ohio. Dr. Bazan is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Urethritis, Gonorrhea, Syphilis, and Chlamydia. Dr. Bazan is currently accepting new patients.

Expertise in
8
conditions
Dr. Octavio Ramilo
Infectious Disease
Expertise in
8
conditions
Dr. Octavio Ramilo
Infectious Disease
Referral may be required

Nationwide Children's Hospital

700 Childrens Dr, 
Columbus, OH 
 (3.5 miles away)
614-722-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Octavio Ramilo is an Infectious Disease provider practicing medicine in Columbus, Ohio. Dr. Ramilo is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Respiratory Syncytial Virus (RSV) Infection, Parainfluenza, Pneumonia, and Sepsis. Dr. Ramilo is currently accepting new patients.

Frequently Asked Questions about Dr. Susan L. Koletar

How do I make an appointment with Dr. Susan L. Koletar?

You can book an appointment with Dr. Susan L. Koletar by calling their office at 614-293-8000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Susan L. Koletar a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Susan L. Koletar is classified as an Distinguished expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Susan L. Koletar specialize in?

While Dr. Susan L. Koletar is a Infectious Disease, they have specific expertise in HIV/AIDS, Myelitis, and AIDS Dementia Complex. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.

Does Dr. Susan L. Koletar participate in research or clinical trials?

Yes. Dr. Susan L. Koletar has published 64 articles and abstracts on conditions like HIV/AIDS. You can view a list of Dr. Susan L. Koletar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Susan L. Koletar accept my insurance?

Dr. Susan L. Koletar accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 614-293-8000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Koletar's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile